Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan;19(1):119-124.
doi: 10.1007/s12094-016-1514-0. Epub 2016 May 4.

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma

F Aya  1   2 , A Fernandez-Martinez  3   4 , L Gaba  3   4 , I Victoria  3   4 , M Tosca  3   4 , E Pineda  3   4 , P Gascon  3 , A Prat  3   4 , A Arance  3   4
Affiliations

Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma

F Aya et al. Clin Transl Oncol. 2017 Jan.

Abstract

Purpose: Immunotherapy (IT) agents and BRAF inhibitors (BRAFi) are effective treatments for patients with advanced BRAF-mutant melanoma although the optimal sequence remains to be elucidated. The aim of this study was to compare the outcomes of two different cohorts of patients treated with BRAFi first, then IT or the reverse sequence.

Patients and methods: This is a retrospective study on two groups of patients: a cohort was treated first with BRAFi followed by immunotherapy (BRAFi-IT) and the other cohort with the reverse sequence (IT-BRAFi). Baseline characteristics and clinical outcomes were compared between the two cohorts.

Results: A total of 25 patients were included in the study. Sixteen patients were given BRAFi-IT sequence and nine received IT-BRAFi sequence. No differences were observed in the characteristics of patients prior to each treatment between cohorts. Objective response rate (ORR) achieved by BRAFi were not different among groups. ORR achieved by IT was higher when administered after BRAFi (43.8 vs 0 %). Survival rates at 1-2 years were similar in both cohorts and median overall survival was not different for BRAFi-IT and IT-BRAFi (log rank test p = 0.97).

Conclusions: No differences were observed in OS between the two cohorts. These results support the indistinct use of IT or BRAFi as initial treatment in patients with metastatic BRAF-mutant melanoma, although higher rate of response to IT was observed when administered after BRAFi. Prospective randomized clinical trials are needed on this issue.

Keywords: BRAF inhibitors; BRAF mutant; Immunotherapy; Melanoma.

PubMed Disclaimer

References

    1. Nat Immunol. 2002 Jul;3(7):611-8 - PubMed
    1. Clin Cancer Res. 2013 Mar 1;19(5):1225-31 - PubMed
    1. Annu Rev Immunol. 2001;19:565-94 - PubMed
    1. Cancer. 2014 Jun 1;120(11):1695-701 - PubMed
    1. Curr Biol. 2005 Feb 8;15(3):249-54 - PubMed

MeSH terms

Substances

LinkOut - more resources